Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

Phase 1

Completed

• Conditions: Urinary Tract Infections
• Interventions: Drug: LBP-EC01; Drug: Placebo

• Registration Number: NCT04191148
• Lead Sponsor: Locus Biosciences

Brief Summary

Study LBx-1001 is a multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LBP-EC01 in patients with indwelling urinary catheters, or requiring intermittent catheterization, and/or patients with asymptomatic bacteriuria caused by Escherichia coli (E. coli). This study population has been selected because LBP-EC01 is a phage cocktail where active bacterial host engagement is required to allow for amplification of the phage and evaluation of the safety and PK of the phage cocktail. Eligible patients will require confirmation of colonization with a urine sample taken within 10 days of randomization that cultures contain ≥10\^3 E. coli colony forming unit (CFU)/mL, without the patient having clinical signs or symptoms of an active urinary tract infection (UTI) requiring antibiotic treatment. Patients should have E. coli as the primary colonizing bacteria and must not have a secondary bacterial colonization at levels equal to or greater than that seen from E. coli.

Detailed Description

Approximately 30 patients 18 years of age or older with a history of urinary tract infection or colonization caused by E. coli who have indwelling urinary catheters, or who require intermittent catheterization, and/or patients with asymptomatic bacteriuria caused by E. coli colonization (≥10\^3 CFU/mL) on microbiological diagnosis, without clinical signs or symptoms of infection requiring antibiotic treatment will be enrolled. Patients will be screened for presence of E. coli colonization (≥10\^3 CFU/mL) prior to randomization and evaluated for potential bacterial susceptibility to LBP-EC01.

Secondary Objective: To evaluate the pharmacodynamics (PD) of LBP-EC01. Exploratory Objective: To explore the influence of LBP-EC01 on the urinary tract microbiota.

Study Timeline

• Study First Submitted: 2019-12-04
• Study First Submitted QC: 2019-12-06
• Study First Posted: 2019-12-09
• Study Start: 2019-12-30
• Primary Completion: 2020-11-19
• Study Completion: 2020-11-19
• Results First Submitted: 2021-09-27
• Status Verified: 2021-11
• Results First Submitted QC: 2022-03-15
• Last Update Submitted: 2022-03-15
• Results First Posted: 2022-03-16
• Last Update Posted: 2022-03-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. Provision of signed and dated informed consent form.

2. Stated willingness to comply with all study procedures and availability for the duration of the study.

3. Males or females 18 years of age or older.

4. Patients with a lower urinary tract colonization caused by E. coli (≥10^3 CFU/mL) and who meet at least one of the following criteria:

   • Has an indwelling urinary catheter and medical documentation of a urinary tract infection by E. coli within the past 12 months
   • Requires intermittent catheterization and medical documentation of a urinary tract infection by E. coli within the past 12 months
   • Has medical documentation of a history of asymptomatic bacteriuria (i.e., lower urinary tract colonization) with E. coli at least once in the past 12 months

5. Patients must have experience with urinary catheterization or have Medical Monitor approval if the patient does not have prior experience with catheterization.

6. In good general health as evidenced by medical history and physical examination.

7. Women of childbearing potential and men with female partners of childbearing potential must use two forms of effective contraception, at least 1 of which is a physical barrier method, during the study and which is recommended to continue for 2 weeks after completing the study.

Read More

Exclusion Criteria

1. Patients with clinical signs of active UTI or other infection requiring antimicrobial treatment. These may include dysuria, urinary frequency, urinary urgency, suprapubic discomfort and flank pain in addition to non-specific symptoms of urinary leakage, change in voiding habits, worsening muscle spasm, increasing autonomic dysreflexia, sweating, malaise, and fever or hypothermia. Analgesic use is permitted.

2. Patients who have received Gram-negative bacteria antimicrobials within 14 days of randomization.

   Note: Patients who are currently only receiving antibiotics with only Gram-positive activity (e.g., vancomycin, daptomycin, linezolid) to treat active infections against Gram-positive non-UTIs can be included in the trial.

3. Presence of a surgically-modified bladder, except for a repaired ruptured bladder.

4. History of severe autonomic dysreflexia, which is defined as those patients who have a spinal cord injury and who have had a documented sudden increase in systolic blood pressure of greater than 40 mm Hg due to an irritation or stimulation (including bladder or bowel irritation) below the level of the spinal cord injury. Autonomic dysreflexia can include findings of hypertensive crisis or emergency, clinically significant bradycardia/tachycardia, severe headache or other severe reaction requiring an acute intervention, so consultation with the Medical Monitor should take place if a history of severe autonomic dysreflexia is suspected but not clearly identified.

5. Active severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease per the investigator's discretion.

6. Any malignancies within the past 5 years (except those in remission).

7. Unless deemed acceptable by the Investigator, prescription drugs, over-the-counter (OTC) medications and supplements that acidify the urine are excluded.

8. Patients who have had allergic reactions to similar compounds, or any excipients.

9. Participation in an investigational drug or device study within 1 month (or 7 half-lives of drug, whichever is longer) prior to randomization.

10. Patients who are pregnant or expecting to conceive, are breast feeding or are planning to breast feed, within 1 month of completion of the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LBP-EC01	LBP-EC01	crPhage cocktail
Placebo	Placebo	Lactated Ringer's solution, injection, USP

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics of LBP-EC01: Tmax	28 days	Time to maximum concentration
Pharmacokinetics of LBP-EC01: Cmax	28 days	Maximum concentration determined directly from the concentration-time profile
Pharmacokinetics of LBP-EC01: AUC	28 days	Area under the concentration versus time curve from time 0 to the last measurable concentration
Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1	35 days	Safety and tolerability of LBP-EC01: Number of participants with treatment-related adverse events as assessed by DAIDS v2.1

Secondary Outcome Measures

Name	Time	Method
Changes in IgE	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through changes in IgE with a positive detection of \>100 IU/mL
Recurrence of E.Coli Colonization or Incidence of Infection Based on Clinical Signs and Symptoms	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through recurrence of E.Coli colonization or incidence of infection based on clinical signs and symptoms
Changes in Immunoglobulin (Ig)A	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through changes in IgA
Reduction in Urinary E.Coli Burden at Any of the Following Time Points: Day 2, Day 3, Day 5, Day 7 (EOT), Day 14 and Day 28	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through reduction in urinary E.coli burden as defined by at least 1 log CFU reduction from baseline.
Time to 1 Logarithmic Reduction in Urinary E.Coli Count From Baseline	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through time to 1 logarithmic reduction in urinary E.coli count from baseline
Changes in IgG	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through changes in IgG with a positive detection of \>1600 mg/dL (\>16.0 g/L)
Changes in IgM	28 days	The secondary objective of this study was to evaluate the pharmacodynamics (PD) of LBP-EC01 through changes in IgM with a positive detection \>230 mg/dL (\>2.3 g/L)

Trial Locations

Locations (7)

Universal Axon - Homestead, LL; 🇺🇸 Homestead, Florida, United States

AMPM Research Clinic; 🇺🇸 Miami Gardens, Florida, United States

Innovation Medical Research Center; 🇺🇸 Palmetto Bay, Florida, United States

Pinnacle Research Group; 🇺🇸 Anniston, Alabama, United States

Tilda Research; 🇺🇸 Irvine, California, United States

Universal Axon Clinical Research; 🇺🇸 Doral, Florida, United States

Ralph H. Johnson VA Medical Center; 🇺🇸 Charleston, South Carolina, United States